非小细胞-话题@MedSci

#非小细胞#

746篇内容 | 6352人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2060060, encodeId=18ad2060060f5, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究, objectType=article, longId=220981, objectId=37d322098186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37d322098186, replyNumber=0, likeNumber=76, createdTime=2022-06-26, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37d322098186, moduleTitle=用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37d322098186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060135, encodeId=576a2060135ac, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, objectType=article, longId=736047, objectId=95aee36047ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95aee36047ae, replyNumber=0, likeNumber=86, createdTime=2022-08-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95aee36047ae, moduleTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95aee36047ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060070, encodeId=a48420600e0fd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效, objectType=article, longId=264985, objectId=1e88264985e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e88264985e4, replyNumber=0, likeNumber=73, createdTime=2022-01-19, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e88264985e4, moduleTitle=Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e88264985e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060043, encodeId=af6a206004348, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较, objectType=article, longId=220149, objectId=2be822014982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be822014982, replyNumber=0, likeNumber=61, createdTime=2022-10-25, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be822014982, moduleTitle=Front Oncol：非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be822014982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060124, encodeId=1393206012452, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=ASCO速递：第一波剧透来了 ——非小细胞转移性专场, objectType=article, longId=727883, objectId=f1dce27883fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1dce27883fb, replyNumber=0, likeNumber=0, createdTime=2022-09-26, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1dce27883fb, moduleTitle=ASCO速递：第一波剧透来了 ——非小细胞转移性专场, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1dce27883fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=301507, objectId=2ec730150e2b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ec730150e2b, replyNumber=0, likeNumber=79, createdTime=2023-01-17, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ec730150e2b, moduleTitle=Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ec730150e2b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060047, encodeId=a1a4206004eac, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=安罗替尼三线以上治疗非小细胞肺癌疗效观察, objectType=article, longId=220699, objectId=4553220699a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4553220699a2, replyNumber=0, likeNumber=51, createdTime=2022-02-04, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4553220699a2, moduleTitle=安罗替尼三线以上治疗非小细胞肺癌疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4553220699a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060091, encodeId=71212060091ae, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=朱慧教授：胸部放疗在非小细胞肺癌中的应用, objectType=article, longId=299323, objectId=9633299323d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9633299323d5, replyNumber=0, likeNumber=33, createdTime=2022-08-22, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9633299323d5, moduleTitle=朱慧教授：胸部放疗在非小细胞肺癌中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9633299323d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060030, encodeId=1e082060030cf, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=今晚7点直播 | 不可手术局部晚期非小细胞肺癌的靶区勾画, objectType=article, longId=218426, objectId=70c521842614, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70c521842614, replyNumber=0, likeNumber=34, createdTime=2021-12-25, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70c521842614, moduleTitle=今晚7点直播 | 不可手术局部晚期非小细胞肺癌的靶区勾画, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70c521842614)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060081, encodeId=5dd12060081d5, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌, objectType=article, longId=294982, objectId=f5d12949827b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d12949827b, replyNumber=0, likeNumber=79, createdTime=2022-04-09, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d12949827b, moduleTitle=Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5d12949827b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060099, encodeId=2d4b2060099d2, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌, objectType=article, longId=301277, objectId=a25e3012e7e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a25e3012e7e9, replyNumber=0, likeNumber=78, createdTime=2023-01-05, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a25e3012e7e9, moduleTitle=重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a25e3012e7e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060078, encodeId=82d420600e8fd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=BMC Cancer: 基线血清胆碱酯酶(ChE)可作为非小细胞肺癌(NSCLC)患者的独立预后指标, objectType=article, longId=294534, objectId=0bab294534a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bab294534a9, replyNumber=0, likeNumber=82, createdTime=2022-05-17, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bab294534a9, moduleTitle=BMC Cancer: 基线血清胆碱酯酶(ChE)可作为非小细胞肺癌(NSCLC)患者的独立预后指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bab294534a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060044, encodeId=f751206004483, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响, objectType=article, longId=220501, objectId=7da92205016e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7da92205016e, replyNumber=0, likeNumber=76, createdTime=2022-08-01, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7da92205016e, moduleTitle=Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7da92205016e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060100, encodeId=d2a820601007a, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布, objectType=article, longId=295920, objectId=7e81295920f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e81295920f9, replyNumber=0, likeNumber=80, createdTime=2022-02-22, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e81295920f9, moduleTitle=帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e81295920f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060033, encodeId=96d62060033cc, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=75岁以上老人非鳞状非小细胞肺癌化疗方案怎么选？, objectType=article, longId=218513, objectId=23892185138a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23892185138a, replyNumber=0, likeNumber=58, createdTime=2022-01-20, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23892185138a, moduleTitle=75岁以上老人非鳞状非小细胞肺癌化疗方案怎么选？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23892185138a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060094, encodeId=cd0820600945d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle= 美国食品药品监督管理局（FDA）批准欧狄沃®（纳武利尤单抗）联合化疗用于特定可切除非小细胞肺癌成人患者新辅助治疗, objectType=article, longId=299862, objectId=d8d4299862bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d4299862bd, replyNumber=0, likeNumber=72, createdTime=2022-10-15, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d4299862bd, moduleTitle= 美国食品药品监督管理局（FDA）批准欧狄沃®（纳武利尤单抗）联合化疗用于特定可切除非小细胞肺癌成人患者新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d4299862bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060087, encodeId=85cb206008eaf, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌, objectType=article, longId=295543, objectId=761e29554381, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=761e29554381, replyNumber=0, likeNumber=64, createdTime=2022-09-30, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=761e29554381, moduleTitle=NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=761e29554381)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060115, encodeId=d24420601159d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=非小细胞肺癌的经典化疗方案系列研究汇总, objectType=article, longId=724550, objectId=d893e2455033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d893e2455033, replyNumber=0, likeNumber=60, createdTime=2022-07-03, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d893e2455033, moduleTitle=非小细胞肺癌的经典化疗方案系列研究汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d893e2455033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060085, encodeId=91152060085d0, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效, objectType=article, longId=295291, objectId=de9929529101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de9929529101, replyNumber=0, likeNumber=74, createdTime=2022-09-12, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de9929529101, moduleTitle=Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de9929529101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060027, encodeId=d152206002e58, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, objectType=article, longId=217997, objectId=faae21e997e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faae21e997e8, replyNumber=0, likeNumber=90, createdTime=2022-04-10, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faae21e997e8, moduleTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faae21e997e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非小细胞

2020-05-29

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究

2022-06-26

zhaojie88 (审核中...)

前往app查看评论内容

#非小细胞#

J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌

2022-08-26

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效

2022-01-19

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较

2022-10-25

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

ASCO速递：第一波剧透来了 ——非小细胞转移性专场

2022-09-26

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效

2023-01-17

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

安罗替尼三线以上治疗非小细胞肺癌疗效观察

2022-02-04

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

朱慧教授：胸部放疗在非小细胞肺癌中的应用

2022-08-22

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

今晚7点直播 | 不可手术局部晚期非小细胞肺癌的靶区勾画

2021-12-25

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌

2022-04-09

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌

2023-01-05

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

BMC Cancer: 基线血清胆碱酯酶(ChE)可作为非小细胞肺癌(NSCLC)患者的独立预后指标

2022-05-17

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响

2022-08-01

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布

2022-02-22

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

75岁以上老人非鳞状非小细胞肺癌化疗方案怎么选？

2022-01-20

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

美国食品药品监督管理局（FDA）批准欧狄沃®（纳武利尤单抗）联合化疗用于特定可切除非小细胞肺癌成人患者新辅助治疗

2022-10-15

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌

2022-09-30

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

非小细胞肺癌的经典化疗方案系列研究汇总

2022-07-03

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效

2022-09-12

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比

2022-04-10

科室
- - 订阅+
  - 更多科室
工具
服务